{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:21:57Z","timestamp":1790626917444,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54GM104938"],"award-info":[{"award-number":["U54GM104938"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI101934"],"award-info":[{"award-number":["U01AI101934"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI082714"],"award-info":[{"award-number":["U19AI082714"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30GM103510"],"award-info":[{"award-number":["P30GM103510"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AR053483"],"award-info":[{"award-number":["P30AR053483"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jaci.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T12:51:14Z","timestamp":1512478274000},"page":"1473-1483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Biomarkers in connective tissue diseases"],"prefix":"10.1016","volume":"140","author":[{"given":"Neelakshi R.","family":"Jog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.10.003_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2017.10.003_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ajhg.2017.06.001","article-title":"Integrative genetic and epigenetic analysis uncovers regulatory mechanisms of autoimmune disease","volume":"101","author":"Shooshtari","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2017.10.003_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrrheum.2014.6","article-title":"Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE","volume":"10","author":"Deane","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5114\/reum.2016.61212","article-title":"Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art\u2014part one","volume":"54","author":"Niklas","year":"2016","journal-title":"Reumatologia"},{"key":"10.1016\/j.jaci.2017.10.003_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5114\/reum.2016.62470","article-title":"Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art\u2014part two","volume":"54","author":"Niklas","year":"2016","journal-title":"Reumatologia"},{"key":"10.1016\/j.jaci.2017.10.003_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/art.40207","article-title":"Rare X chromosome abnormalities in systemic lupus erythematosus and Sjogren's syndrome","author":"Sharma","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/ar2825","article-title":"Why are women predisposed to autoimmune rheumatic diseases?","volume":"11","author":"Oliver","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.003_bib8","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.10.003_bib9","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar3258","article-title":"Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden","volume":"13","author":"Eriksson","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.003_bib10","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/art.20120","article-title":"The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus","volume":"50","author":"McClain","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaut.2016.06.001","article-title":"Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies","volume":"74","author":"Lu","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2017.10.003_bib12","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.40004","article-title":"Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features","volume":"69","author":"Munroe","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaut.2017.07.003","article-title":"Development of autoantibodies precedes clinical manifestations of autoimmune diseases: a comprehensive review","volume":"83","author":"Ma","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2017.10.003_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5152\/eurjrheum.2017.16006","article-title":"Pre-rheumatoid arthritis and its prevention","volume":"4","author":"Paul","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib16","article-title":"Performance of anti-nuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data","author":"Leuchten","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaci.2017.10.003_bib17","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/art.34380","article-title":"Prevalence and sociodemographic correlates of antinuclear antibodies in the United States","volume":"64","author":"Satoh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib18","article-title":"Developing and refining new candidate criteria for SLE classification: an international collaboration","author":"Tedeschi","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaci.2017.10.003_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/acr.21930","article-title":"Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question","volume":"65","author":"Yazdany","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaci.2017.10.003_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2015.12.002","article-title":"Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing","volume":"15","author":"Fritzler","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2017.10.003_bib21","first-page":"321359","article-title":"Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects","volume":"2014","author":"Cozzani","year":"2014","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib23","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib24","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0002-9343(75)90259-4","article-title":"The prognostic and therapeutic implications of DNA:anti-DNA immune complexes in systemic lupus erythematosus (SLE)","volume":"59","author":"Bardana","year":"1975","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2017.10.003_bib26","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/art.20862","article-title":"Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential","volume":"52","author":"Zhao","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJM199805073381906","article-title":"Antibodies to DNA","volume":"338","author":"Hahn","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.10.003_bib28","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2215\/CJN.01910213","article-title":"Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis","volume":"8","author":"Olson","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jaci.2017.10.003_bib29","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.3899\/jrheum.090019","article-title":"Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study","volume":"36","author":"Petri","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib30","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/art.22198","article-title":"The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Tseng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/08916930400022715","article-title":"Anti-Sm and anti-RNP antibodies","volume":"38","author":"Migliorini","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaci.2017.10.003_bib32","doi-asserted-by":"crossref","first-page":"606195","DOI":"10.1155\/2012\/606195","article-title":"Clinical and pathological roles of Ro\/SSA autoantibody system","volume":"2012","author":"Yoshimi","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jaci.2017.10.003_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaut.2008.12.002","article-title":"Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study","volume":"32","author":"Briani","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2017.10.003_bib34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/0961203316676386","article-title":"Anti-ribosomal P antibody: a multicenter study in childhood-onset systemic lupus erythematosus patients","volume":"26","author":"Valoes","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.jaci.2017.10.003_bib35","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/art.22356","article-title":"Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus","volume":"55","author":"Ng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nm0302-295","article-title":"Autoantigen microarrays for multiplex characterization of autoantibody responses","volume":"8","author":"Robinson","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2017.10.003_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2015.12.003","article-title":"SLE-key((R)) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: developing the ImmunArray iCHIP((R))","volume":"429","author":"Putterman","year":"2016","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jaci.2017.10.003_bib38","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3927","article-title":"Autoantibody profiling to follow evolution of lupus syndromes","volume":"14","author":"Olsen","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.003_bib39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ard.45.5.359","article-title":"Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus","volume":"45","author":"Swaak","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib40","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/art.34669","article-title":"Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus","volume":"64","author":"Kalunian","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib41","doi-asserted-by":"crossref","first-page":"e000056","DOI":"10.1136\/lupus-2014-000056","article-title":"Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements","volume":"1","author":"Putterman","year":"2014","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jaci.2017.10.003_bib42","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib43","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/art.37995","article-title":"Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib44","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/art.38573","article-title":"Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare","volume":"66","author":"Munroe","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaut.2016.12.005","article-title":"Pathways of impending disease flare in African-American systemic lupus erythematosus patients","volume":"78","author":"Munroe","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2017.10.003_bib46","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar2816","article-title":"Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study","volume":"11","author":"Schwartz","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.003_bib47","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/art.34426","article-title":"Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis","volume":"64","author":"Brunner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib48","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar3912","article-title":"Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis","volume":"14","author":"Singh","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.003_bib49","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1177\/0961203316644331","article-title":"Urinary high-mobility group box-1 associates specifically with lupus nephritis class V","volume":"25","author":"Jog","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.jaci.2017.10.003_bib50","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1074\/mcp.M112.021667","article-title":"Urinary angiostatin\u2014a novel putative marker of renal pathology chronicity in lupus nephritis","volume":"12","author":"Wu","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.jaci.2017.10.003_bib51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun"},{"key":"10.1016\/j.jaci.2017.10.003_bib52","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1002\/art.30598","article-title":"B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels","volume":"63","author":"Ritterhouse","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib53","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2017.10.003_bib54","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1371\/journal.pmed.0030491","article-title":"Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus","volume":"3","author":"Bauer","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.jaci.2017.10.003_bib55","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2017.10.003_bib56","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib57","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/ard.2008.093146","article-title":"Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus","volume":"68","author":"Landolt-Marticorena","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib58","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0961203309105529","article-title":"Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus","volume":"18","author":"Petri","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.jaci.2017.10.003_bib59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.10092","article-title":"Treating rheumatoid arthritis early: a window of opportunity?","volume":"46","author":"O'Dell","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"suppl\u00a02","key":"10.1016\/j.jaci.2017.10.003_bib60","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar551","article-title":"Autoantibodies in rheumatoid arthritis and their clinical significance","volume":"4","author":"Steiner","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.jaci.2017.10.003_bib61","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","article-title":"Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis","volume":"146","author":"Nishimura","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2017.10.003_bib62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.2006.054445","article-title":"Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis","volume":"66","author":"Turesson","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib63","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1186\/ar3813","article-title":"Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA)","volume":"14","author":"Too","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.003_bib64","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.40066","article-title":"Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients","volume":"69","author":"Demoruelle","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/BOR.0000000000000356","article-title":"Anticitrullinated protein antibodies: origin and role in the pathogenesis of rheumatoid arthritis","volume":"29","author":"England","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib66","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.20044","article-title":"Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study","volume":"50","author":"van Gaalen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib67","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","article-title":"Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the \u2018Orencia and Rheumatoid Arthritis\u2019 registry","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib68","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jbspin.2014.06.001","article-title":"High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis","volume":"81","author":"Gardette","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaci.2017.10.003_bib69","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3899\/jrheum.101086","article-title":"A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis","volume":"38","author":"Svard","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib70","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/ard.2009.116384","article-title":"The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis","volume":"69","author":"van der Woude","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib71","doi-asserted-by":"crossref","first-page":"R142","DOI":"10.1186\/ar1149","article-title":"Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin","volume":"6","author":"Vossenaar","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.003_bib72","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/ar122","article-title":"Insights into rheumatoid arthritis derived from the Sa immune system","volume":"2","author":"Menard","year":"2000","journal-title":"Arthritis Res"},{"key":"10.1016\/j.jaci.2017.10.003_bib73","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3899\/jrheum.140767","article-title":"Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis","volume":"42","author":"Gan","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib74","doi-asserted-by":"crossref","first-page":"e0180144","DOI":"10.1371\/journal.pone.0180144","article-title":"Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients","volume":"12","author":"Vidal-Bralo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2017.10.003_bib75","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/rheumatology\/keu413","article-title":"Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review","volume":"54","author":"Navarro-Compan","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2017.10.003_bib76","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1172\/JCI36389","article-title":"Evidence that cytokines play a role in rheumatoid arthritis","volume":"118","author":"Brennan","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.10.003_bib77","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.27638","article-title":"The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner","volume":"62","author":"Deane","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib78","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1136\/annrheumdis-2015-207911","article-title":"Does the multi-biomarker disease activity score have diagnostic value in early rheumatoid arthritis and unclassified arthritis?","volume":"74","author":"Maijer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib79","first-page":"887","article-title":"Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab","volume":"33","author":"Tony","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib80","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/03009742.2012.754937","article-title":"Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis","volume":"42","author":"Eriksson","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib81","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","article-title":"MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis","volume":"74","author":"Choi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib82","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3899\/jrheum.150998","article-title":"Myeloid-related protein 8\/14 levels in rheumatoid arthritis: marker of disease activity and response to methotrexate","volume":"43","author":"Patro","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.10.003_bib84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib85","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2008.06.010","article-title":"Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies","volume":"7","author":"Koenig","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2017.10.003_bib86","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.003_bib87","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/art.1780331210","article-title":"Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis","volume":"33","author":"Okano","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib88","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3899\/jrheum.110071","article-title":"Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis","volume":"38","author":"Sharif","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib89","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/art.24586","article-title":"Anti-U11\/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis","volume":"61","author":"Fertig","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib90","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.40065","article-title":"Brief report: anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma","volume":"69","author":"Shah","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib91","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib92","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension","volume":"27","author":"Williams","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaci.2017.10.003_bib93","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/ard.2007.082099","article-title":"COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker","volume":"67","author":"Hesselstrand","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib94","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3109\/s10165-011-0568-7","article-title":"Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity","volume":"22","author":"Yanaba","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib95","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/art.38241","article-title":"Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development","volume":"66","author":"Lambrecht","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib96","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1378\/chest.10-0302","article-title":"Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension","volume":"139","author":"Meadows","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2017.10.003_bib97","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar2821","article-title":"Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations","volume":"11","author":"Gourh","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2017.10.003_bib98","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2017.10.003_bib99","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib100","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.10.003_bib101","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s10067-013-2305-4","article-title":"Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A\u00a0correlation with organ involvement and immunological abnormalities","volume":"32","author":"Xu","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib102","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.rmed.2013.03.015","article-title":"Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis","volume":"107","author":"Hesselstrand","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2017.10.003_bib103","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1136\/annrheumdis-2013-205013","article-title":"Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8\/A9 as a novel possible marker for systemic sclerosis phenotype","volume":"73","author":"van Bon","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib104","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.autrev.2014.12.004","article-title":"Churg-Strauss syndrome","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2017.10.003_bib105","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/rheumatology\/keq445","article-title":"Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study","volume":"50","author":"Zwerina","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2017.10.003_bib106","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/ard.2011.155382","article-title":"IgG4 immune response in Churg-Strauss syndrome","volume":"71","author":"Vaglio","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib107","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1002\/art.27678","article-title":"CCL17\/thymus and activation-related chemokine in Churg-Strauss syndrome","volume":"62","author":"Dallos","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib108","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2222.2011.03943.x","article-title":"12-hydroxy-eicosatetraenoic acid (12-HETE): a biomarker of Churg-Strauss syndrome","volume":"42","author":"Szczeklik","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2017.10.003_bib109","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrrheum.2014.104","article-title":"Key advances in the clinical approach to ANCA-associated vasculitis","volume":"10","author":"Kallenberg","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib110","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1046\/j.1523-1755.2000.00080.x","article-title":"Antiproteinase 3- and antimyeloperoxidase-associated vasculitis","volume":"57","author":"Franssen","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.jaci.2017.10.003_bib111","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1002\/art.30560","article-title":"AC13, a C-terminal fragment of apolipoprotein A-I, is a candidate biomarker for microscopic polyangiitis","volume":"63","author":"Takakuwa","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.10.003_bib112","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis","volume":"8","author":"de Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jaci.2017.10.003_bib113","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10157-013-0926-1","article-title":"Retrospective analysis of factors predicting end-stage renal failure or death in patients with microscopic polyangiitis with mainly renal involvement","volume":"18","author":"Kawai","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jaci.2017.10.003_bib114","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/08820139.2017.1288236","article-title":"Differential expression of toll-like receptor signaling pathway is associated with microscopic polyangiitis in peripheral blood neutrophils","volume":"46","author":"Lai","year":"2017","journal-title":"Immunol Invest"},{"key":"10.1016\/j.jaci.2017.10.003_bib115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ki.2010.472","article-title":"New pathophysiological insights\u00a0and treatment of ANCA-associated vasculitis","volume":"79","author":"Wilde","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jaci.2017.10.003_bib116","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2014a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2017.10.003_bib117","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cei.12796","article-title":"Cohen Tervaert JW. The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up","volume":"185","author":"Kemna","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2017.10.003_bib118","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/pr500780a","article-title":"Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1\u00a0autoantibodies from granulomatosis with polyangiitis patients show low levels\u00a0of bisection, galactosylation, and sialylation","volume":"14","author":"Wuhrer","year":"2015","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jaci.2017.10.003_bib119","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ebiom.2017.01.033","article-title":"Galactosylation and sialylation levels of IgG predict relapse in patients with PR3-ANCA associated vasculitis","volume":"17","author":"Kemna","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaci.2017.10.003_bib120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.39814","article-title":"Association of serum calprotectin (S100A8\/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"69","author":"Pepper","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2017.10.003_bib121","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1136\/ard.2010.146456","article-title":"Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's)","volume":"70","author":"Henes","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.10.003_bib122","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/eji.201646810","article-title":"Skewing toward Treg and Th2 responses is a characteristic feature of sustained remission in ANCA-positive granulomatosis with polyangiitis","volume":"47","author":"Szczeklik","year":"2017","journal-title":"Eur J Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917316433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917316433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:06:33Z","timestamp":1758791193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917316433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":122,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0091674917316433"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.10.003","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in connective tissue diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}